US WA: Pushing For Pot In Seattle

The Daily Home, 23 Jun 2013 – SEATTLE (AP) – For the activists who led the effort to legalize recreational marijuana in Washington state last fall, Jamen Shively was one of their biggest fears: an aspiring pot profiteer whose unabashed dreams of building a cannabis empire might attract unwanted attention from the federal government or a backlash that could slow the marijuana reform movement across the country. With visionary zeal, the 45- year-old former Microsoft manager described his plans to a conference room packed with reporters and supporters last month, saying he was tired of waiting for a green light from the Obama administration, which still hasn’t said how it will respond to the legalization of recreational pot in Washington and Colorado. Shively vowed to quickly raise $10 million and eventually build his company, Diego Pellicer, into an international pot powerhouse.

More Headlines

DrugSense

More Headlines

DrugSense

More Headlines

DrugSense

US WA: Ex-Microsoft Manager Wants To Create Marijuana Sales

Boston Herald, 18 Jun 2013 – Jamen Shively , a 45-year-old former Microsoft manager, wants to build a cannabis empire in Washington state, where pot was legalized last fall, saying he was tired of waiting for a green light from the Obama administration, which still hasn’t said how it will respond to the legalization of recreational pot in Washington and Colorado. Shively vowed to quickly raise $10 million and eventually build his company, Diego Pellicer, into an international pot powerhouse. – -Staff and Wire reports. – — MAP posted-by: Jay Bergstrom

US WA: City Lobbies For Tourist Pot Clubs

Seattle Times, 14 Jun 2013 – The city of Seattle embraces pot tourism and wants state regulators to consider allowing private clubs where visitors could consume marijuana, according to a letter sent to state regulators by City Attorney Pete Holmes. Mayor Mike McGinn supports the letter. City Council President Sally Clark said the council has not formally approved it.

More Headlines

DrugSense

More Headlines

DrugSense

More Headlines

DrugSense

More Headlines

DrugSense